Abstract
Purpose
Stereotactic body radiotherapy (SBRT) is an emerging treatment approach reported as safe and effective strategy for low- and intermediate-risk prostate cancer patients. End point of the current study is to appraise the patient-reported quality of life according to the expanded prostate cancer index composite (EPIC) questionnaire.
Methods
In the framework of a prospective mono-institutional phase II trial, EPIC questionnaire was dispensed (up to 1 year after treatment) to a cohort of 46 patients of 72 treated with 5 fractions of 7 Gy each to the prostate. SBRT was delivered with RapidArc VMAT with 10 MV flattening filter-free photon beams.
Results
Median follow-up of patients was 14.5 months (range: 6–23). Acute rectal toxicity was mild (only 23/72 cases with G1–2 and no G3–4) as well as urinary (50/72 G1–2 and no G3–4). At the moment, four cases of G1 late rectal toxicity and 22 cases of G1 urinary (1 of G2) were reported. Urinary, rectal, sexual, and hormonal scores resulted stable over time: 1 year scores resulted, respectively, in −0.3, +2.8, −1.7, and −2.8 % variations with respect to baseline. No significant differences were observed also when data were stratified according to functional and bother sub-scales.
Conclusions
Stereotactic body radiotherapy (SBRT) treatment of prostate with RapidArc and high-intensity photon beams resulted to be well tolerated by patients with mild toxicity profiles and good patient-reported quality of life perception for the first year after treatment. Longer follow-up in the trial cohort is in progress.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alongi F, Cozzi L, Arcangeli S, Iftode C, Comito T, Villa E et al (2013) Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol 8:171
Aznar MC, Petersen PM, Logadottir A, Lindberg H, Korreman SS, Kjaer-Kristoffersen F, Engelholm SA (2010) Rotational radiotherapy for prostate cancer in clinical practice. Radiother Oncol 97:480–484
Bhattasali O, Chen L, Woo J, Park J, Kim J, Moures R et al (2014) Patient reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol 9:52
Greco C (2013) Extreme hypofractionated image-guided radiotherapy for prostate cancer. Eur Med J 1:48–55
Hoppe BS, Michalski JM, Mendenhall NP, Morris CG, Henderson RH, Nichols RC, Mendenhall WM, Williams CR, Regan MM, Chipman JJ, Crociani CM, Sandler HM, Sanda MG, Hamstra DA (2014) Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 120:1076–1082
Katz A, Santoro M, Diblasio F, Ashley R (2013) Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 8:118
King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S et al (2013a) Stereotactic body radiotherapy for localized prostate cancer. Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 109:217–221
King C, Collins S, Fuller D, Wang P, Kupelian P, Steinberg M, Katz A (2013b) Health related quality of life after stereotactic body radiation therapy for localised prostate cancer: results from a multi institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys 87:939–945
Litwin M, Gore J, Kwan L, Brandei J, Lee S, Wither H et al (2007) Quality of life after surgery, external beam irradiation or brachytherapy for early stage prostate cancer. Cancer 109:2239–2247
Macdougall N, Dean C, Muirhead R (2014) Stereotactic body radiotherapy in prostate cancer: is rapidarc a better solution than cyberknife? Clin Oncol 26:4–9
Norkus D, Karklelyte A, Engels B, Versmessen H, Grikevicius R, De Ridder M et al (2013) A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol 8:206
Pesce GA, Clivio A, Cozzi L, Nicolini G, Richetti A, Salati E, Valli M, Vanetti E, Fogliata A (2010) Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy. Radiat Oncol 5:54
Sanda M, Dunn R, Michalski J, Sandler H, Northouse L, Hembroff L et al (2008) Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med 358:1250–1261
Scorsetti M, Alongi F, Castiglioni S et al (2011) Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy treatments. Radiat Oncol 6:113
Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, Mancosu P, Reggiori G, Fogliata A, Torzilli G, Tomatis S, Cozzi L (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86:336–342
Weber DC, Caparrotti F, Laouiti M, Malek K (2011) Simultaneous in-field boost for patients with 1 to 4 brain metastasis/es treated with volumetric modulated arc therapy: a prospective study on quality-of-life. Radiat Oncol 6:79
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG (2000) Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899–905
Wiegner E, King C (2010) Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 78:442–448
Zwahlen DR, Lang S, Hrbacek J, Glanzmann C, Kloeck S, Najafi Y, Streller T, Studer G, Zaugg K, Luetolf UM (2012) The use of photon beams of a flattening filter-free linear accelerator for hypo-fractionated volumetric modulated arc therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 83:1655–1660
Acknowledgments
L. Cozzi acts as Scientific Advisor to Varian Medical Systems and is Head of Research and Technological Development to IOSI, Bellinzona. The study was partially financed by a research Grant of Varian Medical systems.
Conflict of interest
All other co-authors have no conflicts of interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scorsetti, M., Alongi, F., Clerici, E. et al. Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. J Cancer Res Clin Oncol 140, 1795–1800 (2014). https://doi.org/10.1007/s00432-014-1732-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-014-1732-1